These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 37501154)

  • 1. Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies.
    Tapia-Galisteo A; Álvarez-Vallina L; Sanz L
    J Hematol Oncol; 2023 Jul; 16(1):83. PubMed ID: 37501154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Development and Therapeutic Applications of Bispecific Antibodies for Hematologic Malignancies.
    Hays P
    Cancer Treat Res; 2022; 183():287-315. PubMed ID: 35551665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical characterization and comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 trispecific antibodies against B-cell acute lymphoblastic leukemia: targeted immunotherapy for acute lymphoblastic leukemia.
    Wang S; Peng L; Xu W; Zhou Y; Zhu Z; Kong Y; Leung S; Wang J; Yan X; Mi JQ
    Front Med; 2022 Feb; 16(1):139-149. PubMed ID: 34463907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy.
    Tapia-Galisteo A; Compte M; Álvarez-Vallina L; Sanz L
    Theranostics; 2023; 13(3):1028-1041. PubMed ID: 36793863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanobodies in cell-mediated immunotherapy: On the road to fight cancer.
    Maali A; Gholizadeh M; Feghhi-Najafabadi S; Noei A; Seyed-Motahari SS; Mansoori S; Sharifzadeh Z
    Front Immunol; 2023; 14():1012841. PubMed ID: 36761751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cancer therapy using bispecific antibodies].
    Kadowaki N
    Rinsho Ketsueki; 2018; 59(10):1942-1947. PubMed ID: 30305495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager.
    Xiao X; Cheng Y; Zheng X; Fang Y; Zhang Y; Sun R; Tian Z; Sun H
    Front Immunol; 2023; 14():1113303. PubMed ID: 37114050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies.
    Tian Z; Liu M; Zhang Y; Wang X
    J Hematol Oncol; 2021 May; 14(1):75. PubMed ID: 33941237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of a Trispecific Checkpoint Inhibitor and Natural Killer Cell Engager Based on a 2 + 1 Common Light Chain Antibody Architecture.
    Bogen JP; Carrara SC; Fiebig D; Grzeschik J; Hock B; Kolmar H
    Front Immunol; 2021; 12():669496. PubMed ID: 34040611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer.
    Stieglmaier J; Benjamin J; Nagorsen D
    Expert Opin Biol Ther; 2015; 15(8):1093-9. PubMed ID: 25971805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells.
    Gantke T; Weichel M; Herbrecht C; Reusch U; Ellwanger K; Fucek I; Eser M; Müller T; Griep R; Molkenthin V; Zhukovsky EA; Treder M
    Protein Eng Des Sel; 2017 Sep; 30(9):673-684. PubMed ID: 28981915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of novel anti-CD16a antibody clones for the development of effective natural killer cell engagers.
    Liao B; Tumanut C; Li L; Corper A; Challa D; Chang A; Begum H; Farokhi E; Woods C; Fan X
    MAbs; 2024; 16(1):2381261. PubMed ID: 39048914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor model.
    Meckler JF; Levis DJ; Vang DP; Tuscano JM
    Cancer Immunol Immunother; 2023 Sep; 72(9):2939-2948. PubMed ID: 37247022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer therapeutic trispecific antibodies recruiting both T and natural killer cells to cancer cells.
    Kimura K; Kuwahara A; Suzuki S; Nakanishi T; Kumagai I; Asano R
    Oncol Rep; 2023 Dec; 50(6):. PubMed ID: 37859608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of distinct antiviral T-cell immunity: A comparison of bi- and trispecific T-cell engager antibodies with a chimeric antigen receptor targeting HBV envelope proteins.
    Debelec-Butuner B; Quitt O; Schreiber S; Momburg F; Wisskirchen K; Protzer U
    Front Immunol; 2022; 13():1029214. PubMed ID: 36405686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells.
    Lutz S; Klausz K; Albici AM; Ebinger L; Sellmer L; Teipel H; Frenzel A; Langner A; Winterberg D; Krohn S; Hust M; Schirrmann T; Dübel S; Scherließ R; Humpe A; Gramatzki M; Kellner C; Peipp M
    Front Immunol; 2023; 14():1227572. PubMed ID: 37965326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.
    Goebeler ME; Bargou R
    Leuk Lymphoma; 2016 May; 57(5):1021-32. PubMed ID: 27050240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment.
    Bock AM; Nowakowski GS; Wang Y
    Curr Treat Options Oncol; 2022 Feb; 23(2):155-170. PubMed ID: 35182296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.